Suraxavir Marboxil is China's first innovative antiviral drug targeting the Polymerase Acidic (PA) protein. By blocking viral replication at the early stage of the viral cycle, Suraxavir requires a single dose to rapidly reduce viral load, alleviate influenza symptoms, and potentially to reduce the risk of secondary infections.